Sheehan Panic Disorder Scale (SPS)
About the SPS
License Agreement for Use of the SPS
Training for the SPS
Translations and Linguistic Validation of the SPS
How to Cite the SPS
About the SPS
The Sheehan Panic Disorder Scale (SPS) assesses all of the core symptoms of Panic Disorder. It can be used to assess and monitor these symptoms and behaviors over time. It can be either patient-rated or clinician-rated. It has 35 questions to assess a spectrum of symptoms and behaviors associated with Panic Disorder. 16 of these are core Panic Disorder symptoms. The additional 19 questions assess symptoms and behaviors associated with the range of Panic Disorder clinical presentations. The SPS uses a Likert-like response format ranging from “not at all” (0), “a little” (1), “moderately” (2), “markedly” (3), to “extremely” (4). It is designed for use in clinical research studies and in clinical settings as a baseline and treatment outcome measure. It is very sensitive to change and to treatment effects in double-blind, placebo-controlled studies. This scale was previously named as either the Sheehan Clinician Rated Anxiety Scale (SCRAS) or the Sheehan Patient Rated Anxiety Scale (SPRAS). The SPS, the SCRAS, and the SPRAS are identical in all but name.
For any scientific questions relating to the SPS, contact David V Sheehan MD MBA directly by email at: davidVsheehan@gmail.com
To view a watermarked, preview copy of the SPS (click here)
To purchase and download a watermarked, preview copy of the SPS (click here)
Customizable
Dr. Sheehan can design customized versions of the SPS to meet the needs of a specific study or clinical setting. Contact Dr. Sheehan at davidVsheehan@gmail.com to discuss a customized version designed for your needs.
License Agreement for Use of the SPS
Dr. Sheehan licenses the SPS in paper format for distribution as follows : 1) in paper format for any uses; or 2) in fixed pdf form, paper form, or both for use in clinical or academic research trials or studies.
To license the SPS for use there is a charge of $4 per single administration (not per patient enrolled). The amount must be paid in full before study initiation. Email: davidVsheehan@gmail.com for a license agreement.
Training for the SPS
For information about training on the SPS, please contact: davidVsheehan@gmail.com
Translations and Linguistic Validation of the SPS
The non-profit Mapi Research Trust (MAPI) / ICON Language Services, in Lyon, France, is the sole translation service for existing non-English translations for all rating scales and diagnostic interviews that Dr. Sheehan licenses and distributes directly under a license from him.
Dr. Sheehan has collaborated closely with MAPI on these translations for over 15 years and continues to do so. This is to ensure the production of consistent and conceptually equivalent translations of the MINI and its variants and of Dr. Sheehan’s scales, and to be able to provide linguistic validation and certification of these translations. MAPI / Icon Language Services does not distribute the English source language version of the SPS, which is available from Dr. Sheehan directly.
When Dr. Sheehan fully executes your license agreement request, he will provide you with the information to contact MAPI / Icon Language Services to obtain consistent and conceptually equivalent, and linguistically validated translations and the related certificates.
MAPI / Icon Language Services may charge its own usual fees for this work.
How to Cite the SPS
Use the following citations in referencing the SPS:
1. Sheehan, D. V., Raj, A. B., Sheehan, K. H., & Soto, S. (1990). Is Buspirone Effective for Panic Disorder?. Journal of Clinical Psychopharmacology, 10(1), 3-11. PDF: http://journals.lww.com/psychopharmacology/Abstract/1990/02000/Is_Buspirone_Effective_for_Panic_Disorder_.2.aspx
2. Sheehan, D. V., Raj, A. B., Sheehan, K. H., & Soto, S. (1988). The relative efficacy of buspirone, imipramine and placebo in panic disorder: a preliminary report. Pharmacology Biochemistry and Behavior, 29(4), 815-817. DOI: http://dx.doi.org/10.1016/0091-3057(88)90214-6
3. Sheehan, D. V., Raj, A. B., Harnett‐Sheehan, K., Soto, S., & Knapp, E. (1993). The relative efficacy of high‐dose buspirone and alprazolam in the treatment of panic disorder: a double‐blind placebo‐controlled study. Acta Psychiatrica Scandinavica, 88(1), 1-11. DOI: http://dx.doi.org/10.1111/j.1600-0447.1993.tb03405.x
4. Stein, M. B., Heuser, I. J., Juncos, J. L., & Uhde, T. W. (1990). Anxiety disorders in patients with Parkinson’s disease. Am J Psychiatry, 147(2), 217-220. DOI: http://dx.doi.org/10.1176/ajp.147.2.217
5. Munjack, D. J., Bruns, J., Baltazar, P. L., Brown, R., Leonard, M., Nagy, R., Koek, R., Crocker, B., & Schafer, S. (1991). A pilot study of buspirone in the treatment of social phobia. Journal of Anxiety Disorders, 5(1), 87-98. DOI: http://dx.doi.org/10.1016/0887-6185(91)90019-P